Navigation Links
Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
Date:8/13/2009

ABBOTT PARK, Ill., Aug. 13 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced the expansion of the company's XIENCE V(R) USA post-approval study designed to evaluate the safety and effectiveness of the company's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System in a real-world clinical setting out to five years. The expansion allows for more than 2,000 patients from the XIENCE V USA trial to be eligible to cross over into the landmark Dual Anti-Platelet Therapy (DAPT) Trial, an industry-wide collaboration with medical device and pharmaceutical companies.

"The expansion of the XIENCE V USA trial will enable Abbott to enroll more than 2,000 patients who may be eligible to also participate in the DAPT Trial to help advance the body of scientific knowledge regarding the best duration for patients to take blood-thinning medications after a stent procedure," said Charles Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs, and chief medical officer, Abbott Vascular. "We anticipate the DAPT Trial results will be instrumental in establishing definitive guidelines. As an industry leader, Abbott is proud to play a significant role in contributing patients to this important study."

The first patient was enrolled into the XIENCE V USA expansion by James Hermiller, M.D., director, Cardiac Catheterization Labs, The Care Group at St. Vincent Hospital in Indianapolis, Ind. Dr. Hermiller is a principal investigator of the XIENCE V USA trial along with Mitch Krucoff, M.D., FACC, FCCP, director, Cardiovascular Devices Unit, Duke Clinical Research Institute in Durham, N.C.

The XIENCE V USA trial expansion allows for an additional 3,000 patients to be enrolled into Abbott's study, which was originally designed to study 5,
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Abbott HIV Test Demonstrates Earlier Disease Detection
2. Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories
3. Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
4. Abbott Named One of the Top 10 Companies for Scientists
5. HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
6. Abbott to Present at Barclays Global Healthcare Conference
7. Abbott Employee Giving Sets New Records for Employee Participation and Total Donations
8. Abbott Announces 11 Percent Increase in Quarterly Dividend
9. Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
10. Abbott Announces Earnings Guidance for 2009
11. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... the "Middle East & Africa Biomedical Sensors Market ... their offering. The Middle ... estimated at $0.84 billion by 2018 at a CAGR ... near future will bring Biomedical sensors that are adaptable ...
(Date:8/31/2015)... 31, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... and developing innovative therapies primarily in the areas ... 30-day review period following the filing of the ... with the U.S. Food and Drug Administration (FDA) ... Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:8/31/2015)... SAN FRANCISCO, Calif. , Aug. 31, 2015 /PRNewswire/ ... the discovery and development of novel cancer immunotherapies, announced ... M.D., Ph.D., as Chief Executive Officer and William ... Wong and Ho join an experienced management team led ... Jordan Fridman , Ph.D., Chief Scientific Officer; ...
(Date:8/31/2015)... ... August 31, 2015 , ... Regulatory agencies have acknowledged ... development approval process. Thus, innovator companies must understand what will be needed in ... CMO, has been hosting multiple educational panels and seminars for experts to share ...
Breaking Biology Technology:Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3
... Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced financial results ... The net loss for the fourth quarter ended December 31, ... period in 2009. The net loss for the year ended December ... year ended December 31, 2009.   The increase in net loss ...
... at North Carolina State University have developed a ... their alignment and density. The researchers hope the ... of device applications using nanowires, from nanoelectronics to ... plastic and paper. "Alignment is a critical ...
... HONG KONG, Feb. 28, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood ... China,s leading provider of cord blood collection, laboratory testing, hematopoietic ... unaudited financial results for the third quarter and first nine ... Third Quarter of Fiscal ...
Cached Biology Technology:MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 2MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 3MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 4MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 5MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 6MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 7Stretched rubber offers simpler method for assembling nanowires 2China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 2China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 3China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 4China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 5China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 6China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 7China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 8China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 9China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 10China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 11
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 /PRNewswire/ ... www.icg-10.org ) se celebrará por medio de BGI del 22 ... China . Este año, la conferencia ... 2006, ICG se ha convertido en una de las reuniones ... de ser una de las reuniones más dinámicas, entusiastas y ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... at several sites in Pacific Ocean waters off the ... This study is the first to look at caffeine ... conducted by Portland State University master,s student Zoe Rodriguez ... professor of Environmental Science and Management, in collaboration with ...
... of carbon dioxide (CO 2 ) the main cause of ... high of 34 billion tonnes in 2011. In China, the world,s ... 9% to 7.2 tonnes per capita. China is now within the ... major industrialised countries. In the European Union, CO 2 emissions ...
... meeting of the Society for Neuroscience, is the world,s largest ... Learn how the brain works and new developments on ... mental illness, among others. More than 16,000 new discoveries ... world. , Credentialed media can access press conferences and ...
Cached Biology News:PSU study finds 'caffeinated' coastal waters 2Global CO2 emissions continue to increase 2Media registration opens for Neuroscience 2012, world's largest brain science meeting 2
Human Glypican 2 Biotinylated Affinity Purified PAb...
B2-Microgloulin...
... Molecular Imaging's proprietary Focus™ detector technology, while ... the R4. The microPET Focus 120 ... avaiable PET scanner. Focus scanners also ... scinitallor based PETsystems. The combination of ...
...
Biology Products: